CORDIS
EU research results

CORDIS

English EN
A genome-wide mapping and functional genomics approach to elucidating precocious coronary artery disease

A genome-wide mapping and functional genomics approach to elucidating precocious coronary artery disease

Objective

A programme is proposed, by an established European consortium, that will exploit advances in complex trait genetics and functional genomics to discover novel susceptibility genes for coronary artery disease (CAD). The aim is to identify novel proteins and pathways implicated in atherosclerosis and arterial thrombosis in order to define new targets for prevention and treatment and to devise diagnostic tools that identify disease mechanisms in individuals. The PROCARDIS programme has assembled a uniquely large and carefully phenotyped collection of subjects with early CAD: >2600 affected sibling pairs; >1300 two generation 'trios'; > 5000 genetically enriched cases; >5000 matched controls free from CAD. A genome-wide linkage screen has been completed, identifying and replicating a novel locus on chromosome 17; genetic association has already been demonstrated within this, and another, locus. The proposed second phase of PROCARDIS will incorporate: a definitive genome-wide association analysis, substantial new investment in bioinformatics and functional genomics platforms (as will be needed to exploit the linkage and association data), and measurement of novel intermediate phenotypes that will yield biomarkers for CAD risk and quantitative traits for genetic analysis. Additional academic and SME partners have been selected to reinforce the existing consortium, each with unique and complementary expertise, to address the needs of post-genome research. PROCARDIS will integrate a critical mass to attain ambitious and clearly defined objectives; by adopting parallel approaches, the PROCARDIS programme can include 'higher risk' components without endangering the overall outcome. The results will address a priority theme, will give impetus to Europe's competitiveness and will satisfy major societal needs'.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Address

University Offices, Wellington Square
Oxford

United Kingdom

Administrative Contact

Hugh WATKINS (Professor)

Participants (14)

Sort alphabetically

Expand all

KAROLINSKA INSTITUTET

Sweden

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

CONSORTIUM NATIONAL DE RECHERCHE EN GENOMIQUE - CNG

France

INSTITUT DE RECERCA DEL HOSPITAL DE LA SANTA CREU I SANT PAU

Spain

UNIVERSITÀ DEGLI STUDI DI MILANO

Italy

CLINICAL GENE NETWORKS AB

Sweden

ASTRAZENECA

Sweden

DIGILAB BIOVISION GMBH

Germany

METABOMETRIX LIMITED

United Kingdom

COMMISSARIAT A L'ENERGIE ATOMIQUE

France

THE UNIVERSITY OF SURREY

United Kingdom

UPPSALA UNIVERSITET

Sweden

GESELLSCHAFT FÜR ARTERIOSKLEROSEFORSCHUNG E.V.

Germany

CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL

Italy

Project information

Grant agreement ID: 37273

  • Start date

    1 April 2007

  • End date

    30 September 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 13 582 677

  • EU contribution

    € 10 000 000

Coordinated by:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom